bioMérieux share breaks through its €91 resistance but falls back to €90.70
The in vitro diagnostics manufacturer briefly exceeded a technical threshold at the start of trading before retreating below this level. The stock remains close to its recent highs, in a Paris market oriented upwards, and an upgrade from a major brokerage firm published the previous day accompanies this performance.
A €91 resistance broken through then abandoned during the session
bioMérieux shares fell 0.33% to €90.70 while the CAC 40 rose 1.08% and the SBF 120 rose 1.09%. It nevertheless broke through its €91 resistance upwards during trading, reaching a high of €91.40, before falling below this level again (last price noted at €90.65). This back-and-forth is part of solid momentum: the stock gained 5.16% over one week and 13.8% over one month, and remains well above its 20-day moving average (6.27% difference), its 50-day moving average (15.13%) and its 200-day moving average (12.13%).
The RSI at 76 signals an overbought configuration. In the SBF 120 ranking, the stock nevertheless ranks among the weakest of the session, against the trend of an index showing marked gains.
Deutsche Bank upgrades to buy and targets €103 on the stock
On October 28, Deutsche Bank upgraded its rating from "hold" to "buy" and raised its price target from €75 to €103. This target leaves an upside potential of approximately 13.6% compared to the day's price. It comes after a series of developments on the product front: the WHO listed the Biofire Global Fever Special Pathogens panel on its emergency use list on October 19, in the context of the Bundibugyo Ebola outbreak in the Democratic Republic of the Congo.
During the publication of H1 2026 results on July 28, the group had confirmed its outlook for the fiscal year: organic revenue growth between 3% and 5%. The next milestone is set for November 3, with the publication of third quarter 2026 revenue.
